Moomoo AIのまとめ
Novo Integrated Sciences reported financial results for the quarter ended May 31, 2024, with revenues of $3,151,851, a slight decrease from $3,292,933 in the same period last year. The company's operating loss widened to $2,520,203 from $1,430,418 year-on-year, primarily due to increased operating expenses and a significant loss from the change in fair value of derivative liability. Net loss for the quarter was substantial at $13,741,903, compared to $1,497,330 in the previous year, largely impacted by the derivative liability and foreign currency exchange losses. For the nine-month period, revenues increased by 10% to $10,213,661, but the net loss also grew to $21,168,374 from $10,054,098. The company's financial performance was affected by various factors, including changes in product costs, higher operating costs, and increased interest expenses due to...Show More
Novo Integrated Sciences reported financial results for the quarter ended May 31, 2024, with revenues of $3,151,851, a slight decrease from $3,292,933 in the same period last year. The company's operating loss widened to $2,520,203 from $1,430,418 year-on-year, primarily due to increased operating expenses and a significant loss from the change in fair value of derivative liability. Net loss for the quarter was substantial at $13,741,903, compared to $1,497,330 in the previous year, largely impacted by the derivative liability and foreign currency exchange losses. For the nine-month period, revenues increased by 10% to $10,213,661, but the net loss also grew to $21,168,374 from $10,054,098. The company's financial performance was affected by various factors, including changes in product costs, higher operating costs, and increased interest expenses due to a higher average principal balance of convertible notes. Novo Integrated Sciences also highlighted business developments such as the launch of MiTelemed+, the expansion of its healthcare services, and the development of health and wellness products. Looking ahead, the company plans to continue focusing on its three primary pillars: service networks, interconnected technology, and health and wellness products, to drive future growth.
Novo Integrated Sciencesは2024年5月31日に終了した四半期の財務結果を発表し、収益は315万1851ドルで、去年同期の329万2933ドルからわずかに減少しました。同社の営業損失は、主に営業費用の増加と派生負債の公正価値の変化から大幅に増加し、前年の1,430,418ドルから2,520,203ドルに拡大しました。四半期の純損失は軒並み大きく、1,497,330ドルから13,741,903ドルに増加しました。これは、派生負債および外国為替取引による損失の影響が大きかったためです。9か月間の収益は10,213,661ドルに増加しましたが、純損失も10,054,098ドル...すべて展開
Novo Integrated Sciencesは2024年5月31日に終了した四半期の財務結果を発表し、収益は315万1851ドルで、去年同期の329万2933ドルからわずかに減少しました。同社の営業損失は、主に営業費用の増加と派生負債の公正価値の変化から大幅に増加し、前年の1,430,418ドルから2,520,203ドルに拡大しました。四半期の純損失は軒並み大きく、1,497,330ドルから13,741,903ドルに増加しました。これは、派生負債および外国為替取引による損失の影響が大きかったためです。9か月間の収益は10,213,661ドルに増加しましたが、純損失も10,054,098ドルから21,168,374ドルに増加しました。同社の財務パフォーマンスは、製品コストの変化、より高い営業コスト、および転換可能ノートの平均元本残高の増加による高い利息費用など、様々な要因によって影響を受けました。Novo Integrated Sciencesは、MiTelemed+のローンチや、医療サービスの拡大、健康とウェルネス製品の開発などのビジネス開発にも注目しています。今後も、同社はサービスネットワーク、シームレスなテクノロジー、健康とウェルネス製品の3つの主要な柱に注力し、将来の成長を促進する予定です。
役に立った
役に立たない